tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Akero Therapeutics initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Akero Therapeutics (AKRO) with a Buy rating and $76 price target The firm believes the company’s efruxifermin, an FGF21 analog, has a “differentiated” clinical profile and see commercial success in metabolic dysfunction-associated steatohepatitis. Efruxifermin, is in Phase 3 trials with high probabilities of success, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1